IQVIA Holdings Inc. $IQV Shares Sold by South Dakota Investment Council

IQVIA logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • South Dakota Investment Council reduced its IQVIA stake by 65.3%, selling 87,919 shares in the third quarter and retaining 46,750 shares valued at about $12.6 million.
  • IQVIA reported quarterly earnings of $3.34 per share, above the $3.26 consensus estimate, and revenue of $4.43 billion, up 8% year over year.
  • Analysts’ consensus rating was Moderate Buy, with an average price target of $294.21; 18 of 21 analysts rated the stock Buy or Strong Buy.
  • Interested in IQVIA? Here are five stocks we like better.

South Dakota Investment Council cut its stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 65.3% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 46,750 shares of the medical research company's stock after selling 87,919 shares during the quarter. South Dakota Investment Council's holdings in IQVIA were worth $12,569,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. BlackRock Inc. purchased a new stake in IQVIA during the 2nd quarter worth about $2,811,292,000. Dimensional Fund Advisors LP boosted its stake in IQVIA by 4.2% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,657,696 shares of the medical research company's stock worth $282,657,000 after purchasing an additional 66,643 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in IQVIA by 9.0% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,634,264 shares of the medical research company's stock valued at $315,772,000 after buying an additional 134,997 shares in the last quarter. Canada Pension Plan Investment Board purchased a new position in IQVIA during the 2nd quarter valued at about $240,911,000. Finally, Bank of America Corp DE bought a new stake in shares of IQVIA during the second quarter valued at about $235,551,000. 89.62% of the stock is currently owned by institutional investors.

IQVIA Price Performance

IQVIA stock opened at $257.46 on Wednesday. The stock has a market cap of $42.43 billion, a price-to-earnings ratio of 22.86, a PEG ratio of 2.35 and a beta of 1.16. The company has a quick ratio of 0.83, a current ratio of 0.83 and a debt-to-equity ratio of 2.18. The business has a 50-day simple moving average of $267.47 and a 200 day simple moving average of $212.11. IQVIA Holdings Inc. has a 52 week low of $154.50 and a 52 week high of $284.50.

IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings results on Tuesday, October 27th. The medical research company reported $3.34 earnings per share for the quarter, beating the consensus estimate of $3.26 by $0.08. The firm had revenue of $4.43 billion for the quarter, compared to analysts' expectations of $4.37 billion. IQVIA had a return on equity of 30.02% and a net margin of 8.05%. The company's revenue was up 8.0% compared to the same quarter last year. During the same quarter last year, the firm posted $3.00 EPS. On average, research analysts forecast that IQVIA Holdings Inc. will post 11.53 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on IQV shares. Royal Bank Of Canada increased their price target on shares of IQVIA from $247.00 to $319.00 and gave the stock an "outperform" rating in a report on Tuesday, September 29th. Stifel Nicolaus boosted their price objective on shares of IQVIA from $276.00 to $303.00 and gave the company a "buy" rating in a research note on Wednesday, October 14th. Weiss Ratings cut shares of IQVIA from a "hold (c+)" rating to a "sell (d+)" rating in a research note on Wednesday, October 28th. Barclays upped their target price on shares of IQVIA from $275.00 to $300.00 and gave the stock an "overweight" rating in a report on Wednesday, October 7th. Finally, Jefferies Financial Group increased their target price on shares of IQVIA from $220.00 to $290.00 and gave the stock a "buy" rating in a research note on Wednesday, July 29th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $294.21.

Check Out Our Latest Research Report on IQVIA

Insider Activity at IQVIA

In other IQVIA news, insider Eric Sherbet sold 4,446 shares of IQVIA stock in a transaction that occurred on Monday, November 9th. The shares were sold at an average price of $278.83, for a total transaction of $1,239,678.18. Following the completion of the sale, the insider directly owned 24,989 shares in the company, valued at $6,967,682.87. The trade was a 15.10% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider James G. Berkshire sold 2,668 shares of the business's stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $261.33, for a total transaction of $697,228.44. Following the completion of the transaction, the insider directly owned 10,890 shares of the company's stock, valued at approximately $2,845,883.70. This represents a 19.68% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 1.70% of the stock is currently owned by corporate insiders.

IQVIA Company Profile

(Free Report)

IQVIA Holdings Inc. provides clinical research services, healthcare data and analytics, and technology solutions to pharmaceutical, biotechnology, medical-device, and other healthcare organizations. Its services support the development and commercialization of medicines and other healthcare products. The company's offerings include clinical trial planning and management, real-world data and evidence, consulting, and software and technology platforms for life sciences research and commercial operations.

Featured Articles

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV - Free Report).

Institutional Ownership by Quarter for IQVIA (NYSE:IQV)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in IQVIA Right Now?

Before you consider IQVIA, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.

While IQVIA currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines